# Top 10 intervention extracts from PIIS0923753422047810_cleaned.json

=== Ranked Intervention 1 (Extract #6, Therapy) — Score: 5 ===
appro-
Diagnostic procedures
priatedrugs.1Testingismandatoryforoncogenicdriversfor
whichdrugsareapprovedforroutineusage.Broadertesting
Details on diagnostic procedures are covered in the
maybeusedtosupportearlydrugaccessorclinicaltrials.2,3
SupplementaryMaterialSection2,availableat
For personalised therapy approaches, European Society for
10.1016/j.annonc.2022.12.009.SeeSupplementaryFigureS1,
Medical Oncology (ESMO) Scale for Clinical Actionability of
availableat
molecular Targets (ESCAT) classifications4 need to be
aflowchartondiagnosisandtestingbiopsy/cytologysamples
considered (Supplementary Table

=== Ranked Intervention 2 (Extract #2, Treatment) — Score: 3 ===
ntificInstitute,Milan,Italy;15DepartmentofThoracic
Oncology,AirwayResearchCenterNorth,GermanCenterforLungResearch,LungClinic,Grosshansdorf,Germany
Availableonline23January2023
Keywords:ESCAT,ESMOClinicalPracticeGuideline(CPG),ESMO-MCBS,oncogene-addictedmetastaticnon-small-cell
lung cancer (mNSCLC), treatment, targeted therapy
INCIDENCE AND EPIDEMIOLOGY therapy.ThefrequencyofoncogenicdriversinNSCLCaswell
as general discussion of testing strategy and methodology,
Details on incidence and epidemiology are covered in the
including the use of liquid biopsies, can be found in the
Supplementary Material Secti

=== Ranked Intervention 3 (Extract #4, Therapy) — Score: 3 ===
n,Italy;15DepartmentofThoracic
Oncology,AirwayResearchCenterNorth,GermanCenterforLungResearch,LungClinic,Grosshansdorf,Germany
Availableonline23January2023
Keywords:ESCAT,ESMOClinicalPracticeGuideline(CPG),ESMO-MCBS,oncogene-addictedmetastaticnon-small-cell
lung cancer (mNSCLC), treatment, targeted therapy
INCIDENCE AND EPIDEMIOLOGY therapy.ThefrequencyofoncogenicdriversinNSCLCaswell
as general discussion of testing strategy and methodology,
Details on incidence and epidemiology are covered in the
including the use of liquid biopsies, can be found in the
Supplementary Material Section 1, available at

=== Ranked Intervention 4 (Extract #5, Therapy) — Score: 3 ===
logy,AirwayResearchCenterNorth,GermanCenterforLungResearch,LungClinic,Grosshansdorf,Germany
Availableonline23January2023
Keywords:ESCAT,ESMOClinicalPracticeGuideline(CPG),ESMO-MCBS,oncogene-addictedmetastaticnon-small-cell
lung cancer (mNSCLC), treatment, targeted therapy
INCIDENCE AND EPIDEMIOLOGY therapy.ThefrequencyofoncogenicdriversinNSCLCaswell
as general discussion of testing strategy and methodology,
Details on incidence and epidemiology are covered in the
including the use of liquid biopsies, can be found in the
Supplementary Material Section 1, available at
Supplementary Material Section 3,

=== Ranked Intervention 5 (Extract #1, Treatment) — Score: 2 ===
Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical
Practice Guideline for diagnosis, treatment and follow-up
L. E. Hendriks1, K. M. Kerr2, J. Menis3,T. S. Mok4, U. Nestle5,6, A. Passaro7, S. Peters8, D. Planchard9, E. F. Smit10,11,
B. J. Solomon12, G.Veronesi13,14 & M. Reck15, on behalf of the ESMO Guidelines Committee(cid:1)
1DepartmentofPulmonology,GROWSchoolforOncologyandReproduction,Maas

=== Ranked Intervention 6 (Extract #3, Treatment) — Score: 2 ===
E-mail:clinicalguidelines@esmo.org(ESMOGuidelinesCommittee). largegroupofexon20insertionsmostlyresistanttocurrent
5Note:ApprovedbytheESMOGuidelinesCommittee:February2002,last EGFRTKIsbutsensitivetosomeemergingagents(discussed
updateDecember2022.Thispublicationsupersedesthepreviouslypublished in the treatment paragraph including EGFR exon 20 in-
versiondAnnOncol2018;29(Suppl4):iv192-iv237.
sertions). Other mutations, including in exon 18, variably
0923-7534/©2023EuropeanSociety forMedicalOncology. Published by
sensitise, while some mutations confer resistance and may
ElsevierLtd.Allrightsreserved.
Volum

=== Ranked Intervention 7 (Extract #7, Therapy) — Score: 2 ===
e mutations confer resistance and may
ElsevierLtd.Allrightsreserved.
Volume34 - Issue 4 - 2023  339
drive disease relapse. Complete sequencing ofexons 18-21 Resistanceto kinase inhibitorsis almostinevitableandis
by next-generation sequencing (NGS) is strongly recom- variably due to the emergence of therapy-resistanttumour
mended,toidentifyallpossiblesensitisingmutations.Some cell clones with target gene alteration, increased bypass
allele-specific EGFR sequencing solutions do not provide pathwaysignallingand/orphenotypictransformation(small-
complete coverage. EGFR FISH or immunohistochemistry cell,

